SESSION TITLE: COPD Treatment Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM
PURPOSE: To examine characteristics of hospitalized chronic obstructive pulmonary disease (COPD) patients treated with roflumilast.
METHODS: Data were from MarketScan, a large US commercial health insurance claims database. Patients aged ≥40 years with ≥1 hospitalization for COPD (ICD-9: 491, 492, or 496) between 3/1/2011-6/30/2012 were included. Roflumilast group included patients who used roflumilast within 14-days after hospitalization (index), while the comparison group (non-roflumilast) included patients who did not use roflumilast during the study period. Included patients had continuous enrollment at least 6-months before and 30-days after the index date, and those with cystic fibrosis or lung cancer were excluded. Patient baseline characteristics including age, gender, regions, insurance, co-morbidities, exacerbation frequency, COPD medications, and COPD-related and all medical service utilizations were extracted from the 6-months enrollment before the index date. Comparisons were made between patients with and without roflumilast using t-tests for continuous variables and chi-square tests for categorical variables.
RESULTS: A total of 181,311 COPD patients, 367 roflumilast patients and 180,944 non-roflumilast patients, met inclusion/exclusion criteria. Roflumilast patients were younger (68 vs 71 years), with a higher percentage from the Southern US region (37.3% vs 30.1%) and a lower percentage under Medicare insurance (52.6% vs 64.1%) relative to non-roflumilast patients. At baseline period, a higher proportion of roflumilast patients used COPD maintenance medications than non-roflumilast patients (long-acting β2-agonist [LABA] [12% vs 2%], long-acting muscarinic antagonist [58% vs 12%], inhaled corticosteroid [ICS] [19% vs 8%], LABA/ICS combinations [60% vs 16%], and theophylline [13% vs 2%]). Roflumilast patients used more medical services than non-roflumilast patients at baseline (all-cause hospitalization [0.64 vs 0.31], all-cause outpatient visits [21 vs 16], COPD-related hospitalization [0.56 vs 0.12], and COPD-related outpatient visits [9.3 vs 2.7]). All differences were statistically significant.
CONCLUSIONS: Our study showed that prior to use of roflumilast, hospitalized COPD patients had utilized more COPD maintenance medications and medical services at baseline period.
CLINICAL IMPLICATIONS: In the real-world setting, patients hospitalized for COPD and treated with roflumilast tend to be more severe. It is warranted to examine the outcomes associated with roflumilast treatment.
DISCLOSURE: Alex Fu: Other: Research support from Forest Research Institute Shawn Sun: Employee: Employee of Forest Research Institute Xingyue Huang: Employee: Employee of Forest Research Institute Alpesh Amin: Other: Research and Speaker for Forest Research Institute
No Product/Research Disclosure Information